Ebrahimi, Hedyeh http://orcid.org/0000-0003-3647-7356
Dizman, Nazli
Meza, Luis
Malhotra, Jasnoor
Li, Xiaochen
Dorff, Tanya http://orcid.org/0000-0001-5990-298X
Frankel, Paul
Llamas-Quitiquit, Marian
Hsu, Joann
Zengin, Zeynep B. http://orcid.org/0000-0002-2751-5915
Alcantara, Marice
Castro, Daniela http://orcid.org/0000-0002-5423-9821
Mercier, Benjamin
Chawla, Neal
Chehrazi-Raffle, Alex
Barragan-Carrillo, Regina
Jaime-Casas, Salvador http://orcid.org/0009-0009-4334-1300
Govindarajan, Ameish
Gillece, John
Trent, Jeffrey http://orcid.org/0000-0003-0183-4202
Lee, Peter P. http://orcid.org/0000-0002-2660-4377
Parks, Thomas P.
Takahashi, Motomichi http://orcid.org/0000-0003-4773-5904
Hayashi, Atsushi http://orcid.org/0000-0003-4060-2383
Kortylewski, Marcin http://orcid.org/0000-0002-6003-1816
Caporaso, J. Gregory
Lee, Keehoon
Tripathi, Abhishek http://orcid.org/0000-0003-4466-1874
Pal, Sumanta K. http://orcid.org/0000-0002-1712-0848
Article History
Received: 4 February 2024
Accepted: 23 May 2024
First Online: 28 June 2024
Competing interests
: N.D. reports an immediate family member holding stocks and ownership in several pharmaceutical companies unrelated to this work. T.D. has received consulting fees from AstraZeneca, Bayer, Janssen and Sanofi. A.C.-R. has received research funding from Exelixis and has received consulting fees from Exelixis, AVEO and Tempus Labs. P.P.L. is a board member of Osel, Inc. and an inventor on US Patent Application 2023/0149479 (Compositions and methods comprising <i>C</i>. <i>butyricum</i> for the treatment of cancer). T.P.P. is an employee of Osel, Inc. M.T. and A.H. have received personal fees from Miyarisan Pharmaceutical Co., Ltd. J.G.C. is the chief science officer of Cymis Benefit Corporation, unrelated to this work. A.T. has received consulting fees from Deka Biosciences, Aadi Biosciences, Seattle Genetics/Astellas, Exelixis, Bayer and Gilead Sciences and research funding from Corvus Pharmaceuticals, EMD Serono and Aravive, Inc. S.K.P. has received travel support from Ipsen, CRISPR and Exelixis. The other authors declare no competing interests.